Skip to main content

ObsEva SA (OBSV)

NASDAQ: OBSV · IEX Real-Time Price · USD
2.65 0.04 (1.53%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap197.60M
Revenue (ttm)19,000
Net Income (ttm)-82.08M
Shares Out77.95M
EPS (ttm)-1.31
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume816,321
Open2.58
Previous Close2.61
Day's Range2.53 - 2.66
52-Week Range1.86 - 5.55
Beta0.74
AnalystsBuy
Price Target12.00 (+352.8%)
Est. Earnings DateNov 4, 2021

About OBSV

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for pret...

IndustryBiotechnology
IPO DateJan 26, 2017
CEOErnest Loumaye
Employees42
Stock ExchangeNASDAQ
Ticker SymbolOBSV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ObsEva stock is "Buy." The 12-month stock price forecast is 12.00, which is an increase of 352.83% from the latest price.

Price Target
$12.00
(352.83% upside)
Analyst Consensus: Buy

News

ObsEva Presents Linzagolix Data From Uterine Fibroid Trials

ObsEva SA (NASDAQ: OBSV) has announced data from PRIMROSE (1 and 2) Phase 3 study of linzagolix for uterine fibroids. The data were presented at the American Society for Reproductive Medicine (ASRM) 202...

2 days ago - Benzinga

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 S...

- Final results from pilot study of linzagolix for the treatment of severe adenomyosis to be presented in a second poster -

3 days ago - GlobeNewsWire

ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & ...

– Presentation of Phase 3 clinical data on linzagolix for the treatment of uterine fibroids and final results from a pilot study of linzagoli x for the treatment of severe adenomyosis –

4 days ago - GlobeNewsWire

ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix

ObsEva Announce s Relationship with Syneos Health to Commercialize Linzagolix

1 week ago - GlobeNewsWire

7 Hot Penny Stocks to Buy in Q4 for 10-Bagger Potential

These penny stocks have huge potential and solid business fundamentals. As not-so speculative names, they could surge higher sooner or later.

Other symbols:BITFBORRHIVESNDLSOLO
2 weeks ago - InvestorPlace

ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

3 weeks ago - GlobeNewsWire

ObsEva (OBSV) Files NDA for Linzagolix to Treat Uterine Fibroids

ObsEva (OBSV) submits an NDA to the FDA for linzagolix as a potential treatment for uterine fibroids.

1 month ago - Zacks Investment Research

ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids

- If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids -

1 month ago - GlobeNewsWire

ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GENEVA, Switzerland September 7 , 202 1 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today an...

1 month ago - GlobeNewsWire

5 Penny Stocks To Watch For September With Upcoming Events

These penny stocks could be in focus as we turn the page on a new month. The post 5 Penny Stocks To Watch For September With Upcoming Events appeared first on Penny Stocks to Buy, Picks, News and Inform...

Other symbols:BLUCTICPIRS
1 month ago - PennyStocks

7 Hottest Penny Stocks to Pick Up Now

Penny stocks from companies that have reasonable business fundamentals. Stocks that can possibly provide multi-fold returns.

Other symbols:GNUSREISNDLTMBR
2 months ago - InvestorPlace

ObsEva Announces Second Quarter 2021 Financial Results and Business Update

- Linzagolix (Yselty ® ) for uterine fibroids: US New Drug Application filing planned in Q 3 :21 ; European marketing approval recommendation anticipated in Q4:21 -

2 months ago - GlobeNewsWire

ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Liv...

- A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patient s Across Three Randomized , Placebo-Controlled Clinical Trials Published in the Journal of Human Reproduction-

2 months ago - GlobeNewsWire

ObsEva to Present at Upcoming Investor Conferences

GENEVA, Switzerland August 3 , 202 1 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today annou...

2 months ago - GlobeNewsWire

Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigationa...

Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation) i ; agent is being studied in an area of significant unmet need

2 months ago - GlobeNewsWire

Is the Options Market Predicting a Spike in ObsEva (OBSV) Stock?

Investors need to pay close attention to ObsEva (OBSV) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

7 Penny Stocks For Your Watch List This Week If You Like Biotech In July

Looking for biotech penny stocks to watch right now? Here are 7 for your list this week.

3 months ago - PennyStocks

ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting

-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and mini symposia –

3 months ago - GlobeNewsWire

ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyos...

-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo transfer -

3 months ago - GlobeNewsWire

ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021

- D ata from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous p reterm labor to be discussed in an oral presentation -

4 months ago - GlobeNewsWire

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28,...

Geneva, Switzerland  and Boston, MA –  May 31 , 202 1  – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive ...

4 months ago - GlobeNewsWire

ObsEva Announces Proposed Changes to the Composition of its Board of Directors

Geneva, Switzerland and Boston, MA –  May 25 , 202 1  – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive h...

4 months ago - GlobeNewsWire

OBSV Stock: The Big Clinical Trial News Boosting ObsEva Today

Swiss biopharma ObsEva is on course to introduce an oral treatment for uterine fibroids, which affect 80% of women by menopause. The post OBSV Stock: The Big Clinical Trial News Boosting ObsEva Today ap...

5 months ago - InvestorPlace